Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
183 studies found for:    "Peripheral T-cell lymphoma"
Show Display Options
Rank Status Study
1 Recruiting Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study
Condition: Peripheral T-cell Lymphomas
Interventions: Drug: GDP;   Biological: Endostar
2 Completed
Has Results
Treatment of Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: GDPT regimen;   Drug: CHOP regimen
3 Completed CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Alemtuzumab
4 Active, not recruiting Study of Bortezomib Combined With ACVBP in Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Velcade + ACVBP regimen
5 Active, not recruiting
Has Results
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Romidepsin
6 Completed Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: KW-0761 (mogamulizumab)
7 Not yet recruiting Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Chidamide;   Drug: cyclophosphamide;   Drug: adriacin;   Drug: vincristine;   Drug: prednisone
8 Terminated Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: Brentuximab vedotin
9 Completed Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: PXD101
10 Completed
Has Results
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Pralatrexate Injection
11 Recruiting Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma
Condition: Peripheral T Cell Lymphoma
Intervention: Drug: Chidamide
12 Completed E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Condition: Peripheral T-Cell Lymphoma
Intervention: Biological: denileukin diftitox (E7777)
13 Active, not recruiting Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Condition: Peripheral T-cell Lymphoma
Intervention:
14 Not yet recruiting Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma
Condition: Peripheral T Cell Lymphoma
Intervention: Drug: Chidamide with ICE regimen
15 Recruiting Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
Condition: Peripheral T Cell Lymphoma
Intervention: Drug: Chidamide
16 Completed Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas
Condition: Peripheral T-cell Lymphomas
Intervention: Drug: Alemtuzumab (Campath-1H)
17 Completed A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: SP-02L (darinaparsin for injection)
18 Active, not recruiting Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Interventions: Drug: Pralatrexate injection;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
19 Recruiting A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma
Intervention: Drug: SP-02L (darinaparsin for injection)
20 Completed A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: SP-02L (darinaparsin for injection)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.